SAN DIEGO, May 22, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to
public health and safety concerns related to the COVID-19 global
pandemic, recommendations and orders from federal, state and local
authorities, and to support the health and well-being of its
stockholders, employees and others, Arena is changing its 2020
Annual Meeting of Stockholders (the "Annual Meeting") to a
virtual-only format that will be held via live audio webcast. The
virtual Annual Meeting is expected to provide stockholders with the
same rights and opportunities to participate as they would have at
an in-person meeting.
The previously announced date and time of the meeting,
June 12, 2020 at 9:00AM (Pacific Time), will not change. Online
access to the Annual Meeting will begin at 8:45AM Pacific
Time. Stockholders will not be able to attend the Annual
Meeting in person.
Attending the Virtual Meeting as a Stockholder of
Record
Arena's stockholders of record as of
April 20, 2020 (the "Record Date")
can attend the Annual Meeting by accessing the meeting center at
www.virtualshareholdermeeting.com/ARNA2020 and entering the
16-digit control number on the proxy card or Notice of Internet
Availability of Proxy Materials previously received. Instructions
on how to connect to the Annual Meeting and participate via the
Internet, including how to demonstrate proof of stock ownership,
and voting instructions, can be found at
www.virtualshareholdermeeting.com/ARNA2020.
Attending the Annual Meeting as a Beneficial
Owner
Arena has been advised by Broadridge that
beneficial stockholders as of the Record Date (i.e. shares held in
"street name" through an intermediary, such as a bank or broker),
who want to be able attend the Annual Meeting can attend using the
16-digit control number found on the notice and instructions
received from their broker or other nominee.
Attending the Annual Meeting as a Guest
Guests may participate in a listen-only mode. No control number is
required.
Stockholders who do not have their 16-digit control number will
be able to access and listen to the Annual Meeting as Guests but
will not be able to vote their shares or submit questions during
the Annual Meeting.
Voting Shares
Stockholders of record and
beneficial owners will be able to vote their shares electronically
during the Annual Meeting by using the 16-digit control number.
Instructions on how to vote while participating in the Annual
Meeting live via the Internet are posted at
www.virtualshareholdermeeting.com/ARNA2020.
Whether or not stockholders plan to virtually attend the
Annual Meeting, Arena urges them to vote and submit their proxy in
advance of the Annual Meeting by one of the methods described in
the proxy materials for the Annual Meeting.
The proxy
materials, including the proxy card and Notice of Internet
Availability of Proxy Materials, previously distributed along with
the definitive proxy statement will not be updated to reflect the
virtual-only format of the Annual Meeting.
List of Stockholders
A list of stockholders
entitled to vote at the Annual Meeting will be available for
examination for any purpose germane to the Annual Meeting during
normal business hours for ten days prior to the Annual Meeting at
Arena's corporate headquarters. Due to limited staffing and
additional health and safety protocols at Arena's corporate
headquarters during the COVID-19 pandemic, stockholders seeking to
examine the stockholder list are encouraged to call Arena's
Investor Relations team at 858.453.7200 to make arrangements. The
stockholder list and instructions will also be available during the
Annual Meeting at www.virtualshareholdermeeting.com/ARNA2020.
About Arena Pharmaceuticals
Arena
Pharmaceuticals is uniquely positioned to develop best-in-disease
medicines with optimized efficacy and safety for patients globally.
Our drive to deliver a robust pipeline of novel, transformational
medicines is grounded in two decades of world class
G-protein-coupled receptor (GPCR) discovery research.
It is the breadth and depth of our portfolio, prioritization of
drug development to meet unmet patient needs, strong financial
health and growing, bold-thinking world-class team that gives Arena
the ingredients and passion to build a sustainable, vibrant next
generation pharmaceutical company.
Forward-Looking Statements
Certain statements
in this press release are forward-looking statements that involve a
number of risks and uncertainties. Such forward-looking statements
include statements about Arena's position, drive, portfolio,
prioritization, financial position, team, and building of the
company. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include those disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate
Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
mknight@arenapharm.com
858.210.3635
Arena Media Contact:
IR@arenapharm.com
858.453.7200
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholders-301064464.html
SOURCE Arena Pharmaceuticals, Inc.